Insmed Announces CFO Transition
Key Highlights
- ➤Sara Bonstein will step down as CFO on October 30, 2026, after nearly seven years.
- ➤Insmed reaffirms 2026 BRINSUPRI revenue guidance of $1.25 billion to $1.40 billion.
- ➤Insmed reaffirms 2026 ARIKAYCE revenue guidance of $450 million to $470 million.
- ➤Company says CFO transition is unrelated to accounting, financial statements, controls, or operations disagreements.
- ➤Insmed expects to reach cash flow positivity next year, according to CEO Will Lewis.
Expert Statements
Will Lewis, Chair and Chief Executive Officer of Insmed
“We are grateful for Sara's many contributions over the past almost seven years and her dedicated leadership overseeing our finance organization during a time when Insmed raised more than $4.2 billion in capital.”
Will Lewis, Chair and Chief Executive Officer of Insmed
“We are now well positioned to reach cash flow positivity next year with what we view as a clear path toward sustained top-line growth and bottom-line profitability.”
Sara Bonstein, Chief Financial Officer of Insmed
“Serving as Insmed's CFO has been a privilege of my career.”
Sara Bonstein, Chief Financial Officer of Insmed
“I am thankful for our team and all we achieved together during my time with the Company.”
Sara Bonstein, Chief Financial Officer of Insmed
“I am confident in Insmed's future, especially given our successful launch of BRINSUPRI coupled with our exciting pipeline.”
Sara Bonstein, Chief Financial Officer of Insmed
“After considerable reflection, now is an ideal time for me to pursue my ambition for a broader leadership role.”
Will Lewis, Chair and Chief Executive Officer of Insmed
“Sara has been a steadfast partner in building Insmed into the company we are today, and we wish her well as she pursues her next leadership opportunity.”
Will Lewis, Chair and Chief Executive Officer of Insmed
“Insmed has undergone a major transformation in recent years to become a global diversified biotech company with a robust portfolio of first- or best-in-class therapies with the potential to deliver meaningful impact for patients with serious diseases.”
Will Lewis, Chair and Chief Executive Officer of Insmed
“With BRINSUPRI and ARIKAYCE on track to deliver meaningful revenue this year, and with substantial growth expected in the years ahead through our commercial portfolio and diverse therapeutic pipeline, we remain focused on delivering on our long-term ambitions.”
Will Lewis, Chair and Chief Executive Officer of Insmed
“We are committed to ensuring our finance operations continue supporting Insmed's success in our next phase of growth, and we have partnered with a leading executive search firm to identify our next CFO.”
—Sara Bonstein Will Step Down as CFO on October 30 After Nearly Seven Years of Dedicated Leadership—
—Company Announces Third-Quarter 2026 Financial Results Conference Call to Be Held on Thursday, October 29, 2026—
Get started
Create a free account to read the full story.